Neuropsychiatry: The Definitive 2025 Analysis of Investment & Scientific Breakthroughs
Executive Summary For decades, neuropsychiatry was a field characterized by high failure rates and incremental progress, making it a challenging ...
Tag: Cybin
Unpacking Biotech’s Future: Inside RTW Investments’ Strategy with Roderick Wong
Investor Insights Podcast #55 featuring Dr. Roderick Wong, Founder and CIO of RTW Investments, offers a deep dive into the ...
FDA Commissioner: Psychedelic Research a “Top Priority” — Companies Like Cybin, MindMed, and Compass Pathways Lead the Charge
In a recent interview on NewsNation's On Balance, FDA Commissioner Dr. Marty Makary affirmed that advancing psychedelic therapies is now ...
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
- 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just ...
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion ...
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH ™ : A P hase ...
Popular Stories
-
Cybin Inc: The Psychedelic Revolution in Mental Health Treatment is Here
-
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
-
BlackRock Bitcoin ETF Sees Rally: What’s Next for IBIT?
-
Universal Digital Inc. (Formerly Minas Metals Ltd.) Announces Completion of Change of Business
-
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Small Cap Bulls is your trusted source for uncovering small-cap companies on the brink of explosive growth. With in-depth analysis and expert insights, we help investors navigate the dynamic world of small-cap stocks. Join us as we charge ahead, empowering your investment journey.
2024 Small Cap Bulls – Charging Ahead. All Rights Reserved.
By using this site you agree to the Terms of Use, Privacy Policy, and Service Agreement.
Navigate
stay connected
Join our newsletter